Search results for "CTL"

showing 10 items of 521 documents

Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo.

1996

Peptide epitopes derived from differentiation antigens of the melanocyte lineage were recently identified in human melanomas as targets for MHC-restricted cytotoxic T lymphocytes (CTL). The characterization of multiple CTL-defined antigenic determinants has opened possibilities of development of antigen-targeted vaccines. In the present study, we determined CTL reactivity against melanoma-associated peptides derived from Melan A/MART-1, tyrosinase, and gp100/Pmel17 in 3 HLA-A2+ melanoma patients. Then, we assessed the immune responses to synthetic melanoma-associated peptides injected intradermally. After 3 cycles of immunization with peptide alone, we used systemic GM-CSF as an adjuvant du…

MaleCancer ResearchCellular immunitymedicine.medical_treatmentMolecular Sequence Data10050 Institute of Pharmacology and Toxicology610 Medicine & healthchemical and pharmacologic phenomenaActive immunizationEpitopeImmune systemAntigenAdjuvants ImmunologicAntigens NeoplasmmedicineCytotoxic T cellHumans1306 Cancer ResearchHypersensitivity DelayedAmino Acid SequenceMelanomabusiness.industryGranulocyte-Macrophage Colony-Stimulating FactorImmunotherapyMiddle AgedImmunohistochemistryNeoplasm ProteinsCTL*OncologyImmunology570 Life sciences; biology2730 OncologyFemaleImmunizationbusinessMelanoma-Specific AntigensT-Lymphocytes CytotoxicInternational journal of cancer
researchProduct

Serum S100B levels correlate with clinical benefit in a metastatic melanoma patient treated by CTLA-4 blockade: a case report.

2013

<b><i>Background:</i></b> Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) is an immunoregulatory molecule expressed by activated T cells. In patients with metastatic melanoma, anti-CTLA-4 antibody therapy with ipilimumab achieves durable cancer regression in approximately 10-15% of patients. In the face of complex and sometimes delayed tumor response patterns, prognostic and predictive biomarkers are needed to monitor therapy outcomes and to identify early potential long-term survivors who might also benefit from therapy re-induction. <b><i>Case Report:</i></b> The clinical case of a 49-year-old male patient with metastatic melanoma and u…

MaleCancer ResearchMetastatic melanomamedicine.drug_classmedicine.medical_treatmentStatistics as TopicAntineoplastic AgentsS100 Calcium Binding Protein beta SubunitMonoclonal antibodySensitivity and SpecificitymedicineBiomarkers TumorCytotoxic T cellHumansCTLA-4 AntigenMelanomabusiness.industryMelanomaAntibodies MonoclonalReproducibility of ResultsHematologyImmunotherapyMiddle Agedmedicine.diseaseIpilimumabBlockadeTreatment OutcomeOncologyCTLA-4Cancer researchBiomarker (medicine)businessOnkologie
researchProduct

Phase I trial of thymidylate synthase poly-epitope peptide (TSPP) vaccine in advanced cancer patients.

2015

Thymidylate synthase (TS) poly-epitope peptide (TSPP) is a 27-mer peptide vaccine containing the amino acidic sequences of three epitopes with HLA-A2.1-binding motifs of TS, an enzyme overexpressed in cancer cells, which plays a crucial role in DNA repair and replication. Based on the results of preclinical studies, we designed a phase Ib trial (TSPP/VAC1) to investigate, in a dose escalation setting, the safety and the biological activity of TSPP vaccination alone (arm A) or in combination with GM-CSF and IL-2 (arm B) in cancer patients. Twenty-one pretreated metastatic cancer patients, with a good performance status (ECOG ≤ 1) and no severe organ failure or immunological disease, were enr…

MaleCancer Researchmedicine.medical_treatmentImmunologyPharmacologyThymidylate synthaseCancer VaccinesCTLsNeoplasmsCancer vaccineMedicineImmunology and AllergyHumansImmune responseAdverse effectAgedbiologyPerformance statusbusiness.industryPhase Ib trialCancerImmunotherapyThymidylate SynthaseMiddle Agedmedicine.diseaseCancer vaccine; CTLs; Immune response; Immunotherapy; Phase Ib trial; Cancer Research; Oncology; Immunology; Immunology and AllergyOncologyCTLImmunologyToxicityVaccines Subunitbiology.proteinPeptide vaccineFemaleCancer vaccineImmunotherapybusinessCancer immunology, immunotherapy : CII
researchProduct

Discover cervical disc arthroplasty versus anterior cervical discectomy and fusion in symptomatic cervical disc diseases: A meta-analysis.

2016

OBJECTIVE:Symptomatic cervical disc disease (SCDD) is a common degenerative disease, and Discover artificial cervical disc, a new-generation nonconstrained artificial disk, has been developed and performed gradually to treat it. We performed this meta-analysis to compare the efficacy and safety between Discover cervical disc arthroplasty (DCDA) and anterior cervical discectomy and fusion (ACDF) for SCDD. METHODS:An exhaustive literature search of PubMed, EMBASE, and the Cochrane Library was conducted to identify randomized controlled trials that compared DCDA with ACDF for patients suffering SCDD. A random-effect model was used. Results were reported as standardized mean difference or risk …

MalePhysiologymedicine.medical_treatmentSensory Physiologylcsh:MedicineAnterior cervical discectomy and fusionIntervertebral Disc DegenerationCochrane LibraryOssificationlaw.invention0302 clinical medicineMathematical and Statistical TechniquesRandomized controlled triallawMedicine and Health SciencesRange of Motion Articularlcsh:ScienceIntervertebral DiscRandomized Controlled Trials as Topic030222 orthopedicsProstheticsMultidisciplinaryMiddle AgedSensory SystemsTreatment OutcomeSomatosensory SystemResearch DesignMeta-analysisPhysical SciencesCervical VertebraeFemaleBone RemodelingRange of motionIntervertebral Disc DisplacementStatistics (Mathematics)DiskectomyResearch ArticleBiotechnologyAdultmedicine.medical_specialtyDrug Research and DevelopmentClinical Research DesignSurgical and Invasive Medical ProceduresResearch and Analysis MethodsArthroplasty03 medical and health sciencesMusculoskeletal System ProceduresmedicineHumansClinical TrialsStatistical MethodsPharmacologybusiness.industrylcsh:RBiology and Life SciencesPain SensationArthroplastyRandomized Controlled TrialsSurgeryAssistive TechnologiesStrictly standardized mean differenceRelative risklcsh:QMedical Devices and EquipmentAdverse EventsClinical MedicinebusinessPhysiological Processes030217 neurology & neurosurgeryMathematicsMeta-AnalysisNeurosciencePloS one
researchProduct

Docosahexaenoic acid reduces suppressive and migratory functions of CD4CD25 regulatory T-cells

2009

Immunological tolerance is one of the fundamental aspects of the immune system. The CD4(+)CD25(+) regulatory T (Treg) cells have emerged as key players in the development of tolerance to self and foreign antigens. However, little is known about the endogenous factors and mechanisms controlling their suppressive capacity on immune response. In this study, we observed that docosahexaenoic acid (DHA), an n-3 polyunsaturated fatty acid, diminished, in a dose-dependent manner, the capacity of Treg cells to inhibit the CD4(+)CD25(-) effector T-cell proliferation. DHA not only reduced the migration of Treg cells toward chemokines but also downregulated the mRNA expression of CCR-4 and CXCR-4 in Tr…

MaleReceptors CXCR4Chemokineextracellular signal-regulated kinase 1/2Receptors CCR4Docosahexaenoic Acidschemical and pharmacologic phenomenaQD415-436T-Lymphocytes RegulatoryBiochemistryMicehistone desacetylase 7EndocrinologyImmune systemAntigenAntigens CDCell MovementTransforming Growth Factor betaAnimalsCTLA-4 AntigenRNA MessengerIL-2 receptorCells CulturedCell ProliferationDose-Response Relationship DrugbiologySmad7Reverse Transcriptase Polymerase Chain ReactionInterleukin-2 Receptor alpha SubunitFOXP3Forkhead Transcription Factorshemic and immune systemsCell BiologyTransforming growth factor betaInterleukin-10Cell biologyMice Inbred C57BLInterleukin 10Docosahexaenoic acidImmunologybiology.proteinResearch ArticleJournal of Lipid Research
researchProduct

Intermittent administration of parathyroid hormone improves the repairing process of rat calvaria defects: A histomorphometric and radiodensitometric…

2014

Background: The aim of this study was to evaluate the effects of intermittent treatment of parathyroid hormone (PTH (1-34)) on the bone regeneration of critically-sized rat calvarial bone defects. Material and Methods: Thirty-two male rats were trephined (4mm fullthickness diameter), in the central part of the parietal bones and divided into 2 groups of 16. The PTH group received subcutaneous injections of PTH (1-34) at 40μg/kg, 3 times a week and the control (CTL) group received the vehicle in the same regimen. The rats were sacrificed at 4 weeks post-treatment regimen, the parietal bones were extracted and samples were evaluated through histomorphometry and radiodensitometry. Results: The…

Malemedicine.medical_specialtyBone RegenerationBone densityParathyroid hormoneCalvariaOdontologíaBone DensityInternal medicinemedicineAnimalsRats WistarBone regenerationGeneral DentistryBone mineralWound Healingbusiness.industryResearchSkull:CIENCIAS MÉDICAS [UNESCO]Ciencias de la saludRatsRadiographySkullCTL*medicine.anatomical_structureEndocrinologyOtorhinolaryngologyParathyroid HormoneUNESCO::CIENCIAS MÉDICASSurgeryOral SurgerybusinessWound healing
researchProduct

Facing the dawn of immunotherapy for hepatocellular carcinoma.

2013

In this study, administration of tremelimumab was accompanied by a tolerable toxicity profile, most frequently including skin rash (65%), fatigue (55%), and anorexia (50%). During the initial course of tremilimumab, a transient increase of serum transaminase activity was observed. Hepatotoxicity did not impair liver function, even in the context of Child-Pugh B cirrhosis and hepatitis C. Therapy was stopped in 3 patients before tumor response evaluation was completed due to tremilimumab-related diarrhea or clinical deterioration, which was not associated with the treatment regimen. The relevance of this study is strengthened by the inclusion of HCC patients, showing hepatitis C associated c…

Malemedicine.medical_specialtyCirrhosisCarcinoma HepatocellularHepatitis C virusAntineoplastic Agentsmedicine.disease_causeAntibodies Monoclonal HumanizedGastroenterologyAntiviral AgentsInternal medicinemedicineHumansCTLA-4 AntigenHepatitisHepatologybusiness.industryLiver NeoplasmsAntibodies MonoclonalHepatitis CHepatitis C Chronicmedicine.diseaseRashHepatocellular carcinomaImmunologyFemaleLiver functionmedicine.symptombusinessTremelimumabmedicine.drugJournal of hepatology
researchProduct

Late-onset myasthenia gravis - CTLA4(low) genotype association and low-for-age thymic output of naïve T cells.

2014

Abstract Late-onset myasthenia gravis (LOMG) has become the largest MG subgroup, but the underlying pathogenetic mechanisms remain mysterious. Among the few etiological clues are the almost unique serologic parallels between LOMG and thymoma-associated MG (TAMG), notably autoantibodies against acetylcholine receptors, titin, ryanodine receptor, type I interferons or IL-12. This is why we checked LOMG patients for two further peculiar features of TAMG – its associations with the CTLA4 high/gain-of-function  +49A/A genotype and with increased thymic export of naive T cells into the blood, possibly after defective negative selection in AIRE-deficient thymomas. We analyzed genomic DNA from 116 …

Malemedicine.medical_specialtyGenotypeThymomaT-LymphocytesImmunologyDNA Mutational AnalysisRecent Thymic EmigrantLate onsetCell CountThymus GlandBiologyPeripheral blood mononuclear cellWhite PeopleGene FrequencyInternal medicineGenotypeMyasthenia GravismedicineImmune ToleranceImmunology and AllergyHumansCTLA-4 AntigenGenetic Predisposition to DiseaseGenetic Association StudiesAgedPeripheral tolerance inductionAged 80 and overPolymorphism GeneticThymocytesT-cell receptor excision circlesAutoantibodyCell DifferentiationThymus NeoplasmsMiddle Agedmedicine.diseaseMyasthenia gravisEndocrinologyImmunologyFemaleJournal of autoimmunity
researchProduct

Exercise for depression in older adults: a meta-analysis of randomized controlled trials adjusting for publication bias

2016

OBJECTIVE: To evaluate the antidepressant effects of exercise in older adults, using randomized controlled trial (RCT) data. METHODS: We conducted a meta-analysis of exercise in older adults, addressing limitations of previous works. RCTs of exercise interventions in older people with depression (≥ 60 years) comparing exercise vs. control were eligible. A random-effects meta-analysis calculating the standardized mean difference (SMD) (95% confidence interval [95%CI]), meta-regressions, and trim, fill, and fail-safe number analyses were conducted. RESULTS: Eight RCTs were included, representing 138 participants in exercise arms and 129 controls. Exercise had a large and significant effect on…

Malemedicine.medical_specialtylcsh:RC435-571Subgroup analysisReview Articlenot knownlaw.invention03 medical and health sciences0302 clinical medicinePhysical medicine and rehabilitationRandomized controlled triallawRisk Factorslcsh:PsychiatryMedicineHumans030212 general & internal medicineExerciseolder adultsAgedRandomized Controlled Trials as Topicpublication biasAged 80 and overDepressive Disorder Majorbusiness.industryAge FactorsPublication biasMiddle AgedConfidence intervalExercise Therapymeta-analysisPsychiatry and Mental healthTreatment OutcomeStrictly standardized mean differenceMeta-analysisdepressionPhysical therapyFemalebusinessAnaerobic exercise030217 neurology & neurosurgeryManagement of depressionBrazilian Journal of Psychiatry
researchProduct

Effectiveness of Exergame Intervention on Walking in Older Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

2020

Abstract Objective The objective of this review was to systematically evaluate the effectiveness of exergaming on walking in older adults. In addition, the aim was to investigate the relationship between the exergaming effect and age, baseline walking performance, exercise traits, technology used, and the risk of bias. Methods A literature search was carried out in the databases MEDLINE, CINAHL, CENTRAL, EMBASE, WoS, PsycInfo, and PEDro up to January 10, 2020. Studies with a randomized controlled trial design, people ≥60 years of age without neurological disorders, comparison group with other exercise or no exercise, and walking-related outcomes were included. Cochrane RoB2, meta-analysis, …

Malemedicine.medical_specialtymedicine.medical_treatmentMEDLINEPsychological interventionPhysical Therapy Sports Therapy and RehabilitationHealth PromotionWalkingPsycINFOCINAHLlaw.inventionRandomized controlled triallawHumansMedicineMuscle StrengthExerciseAgedRandomized Controlled Trials as TopicRehabilitationbusiness.industryAge FactorsExercise TherapyVideo GamesStrictly standardized mean differenceMeta-analysisPhysical therapyFemalebusinessAttitude to HealthPhysical Therapy
researchProduct